Omnix Medical founded in 2015, is developing novel antibiotic agents for the treatment of hospital-acquired infections involving drug resistant bacteria. Omnix’s technology is based on natural antimicrobial peptides, biochemically engineered to be compatible for therapeutic applications. Omnix’s lead molecule, OMN6, employs a unique mechanism of action, representing a new antibiotic class, characterized by a rapid-bactericidal effect. OMN6 was found to be active irrespective of resistance to other antibiotic drugs, and thus, offers a safer more efficient alternative to current therapies.
Dr. Moshik Cohen-Kutner Co-Founder & CEO
Dr. Niv Bachnoff Co-Founder & CSO
Mr. Rom Lakritz CPA, Co-Founder & CFO/COO
Ms. Shira Merchavia Research Director
Ms. Janna Michaeli Preclinical Director
Dr. Jonathan Zazun PharmD, CMC Director
Ms. Noa Nur Research Scientist
Ms. Esti Rotshtein Operations Manage